---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000057"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:35:34.054928+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M

## Summary
- FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.
- Phase 3 MG trial initiation on track by end of June 2022; top-line data expected H2 2024.
- Cash $493.8M as of March 31, 2022 provides runway into calendar year 2025.
- FY2022 net loss $156.7M ($1.43/share) vs FY2021 $107.4M ($1.22/share); R&D spend $101.8M.
- Company expects to announce two new batoclimab indications by August 2022.

## SEC filing metadata
- accession: 0001764013-22-000057
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/0001764013-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/imvt-20220608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000057
- JSON: https://secwatch.observer/filing/0001764013-22-000057.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.